| Followers | 1106 |
| Posts | 279775 |
| Boards Moderated | 10 |
| Alias Born | 03/18/2011 |
Friday, November 18, 2011 1:00:34 PM
FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
| 10:50 AM | |
OTC and PINK news - 11-18-2011
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the FDA Commissioner is revoking the approval of Avastin® (bevacizumab) for the treatment of mBC in the United States. “We are disappointed with the outcome. We remain committed to the many women with this incurable disease and will continue to provide help through our patient support programs to those who may be facing obstacles to receiving their treatment in
Attachment: ViewMedia (2.0 KB)
Related News: Similar Content http://feeds.businesswire.com/click.phdo?i=7755c366893d0bdbff41af709dd3f854#rssowlmlink
OTC and PINK news - 11-18-2011
| 10:50 AM | |
OTC and PINK news - 11-18-2011
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the FDA Commissioner is revoking the approval of Avastin® (bevacizumab) for the treatment of mBC in the United States. “We are disappointed with the outcome. We remain committed to the many women with this incurable disease and will continue to provide help through our patient support programs to those who may be facing obstacles to receiving their treatment in
Attachment: ViewMedia (2.0 KB)
Related News: Similar Content http://feeds.businesswire.com/click.phdo?i=7755c366893d0bdbff41af709dd3f854#rssowlmlink
OTC and PINK news - 11-18-2011
My stuff http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64797507
Never, invest with money you need to survive. Diversify, patience, set tight stops. $20 or less in commission fees is almost always cheaper than a 5-40%+ drop in share value.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
